RBC Positive on Sarepta Therapeutics (SRPT) Into Tomorrow's R&D Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Sarepta Therapeutics (SRPT) PT Raised to $203 at Goldman Sachs
June 20, 2018 8:38 AM EDTGoldman Sachs raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $203.00 (from $127.00) while maintaining a Buy rating following the company's R&D day. SRPT reported highly encouraging preliminary Ph1/2 NCH micro-dystrophin gene therapy data from cohort B for the three initially-dosed patients... More
Sarepta Therapeutics (SRPT) PT Raised to $170 at BTIG
June 20, 2018 7:16 AM EDTBTIG raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $170.00 (from $120.00) while maintaining a Buy rating. Analyst Timothy Chiang continues to see SRPT as a disruptor in the Duchenne Muscular Dystrophy treatment market with its pipeline of gene therapy and RNA-splicing product... More
Sarepta Therapeutics (SRPT) DMD Gene Therapy Results 'Really Positive' - Baird
June 19, 2018 10:42 AM EDTBaird analyst Brian Skorney calls Sarepta Therapeutics (NASDAQ: SRPT) DMD gene therapy results "really positive."
Skorneycommented, "The initial results, in two patients, are beyond encouraging. We think this data could indicate levels of expression that could be functionally converting patients from a... More
Sarepta Therapeutics' (SRPT) Gene Therapy Shows Promising Early Results in DMD Study - Bloomberg
June 19, 2018 10:21 AM EDTPreliminary Phase 1/2a of Sarepta Therapeutics' (NASDAQ: SRPT) gene therapy for DMD showed an average of 38% of micro-dystrophin compared to normal utilizing its method of measurement. Analysts expectations were for a 10%-15% gain, according to Bloomberg.
... More